Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
RECURSION PHARMACEUTICALS, INC. Chief Financial Officer Ben R. Taylor reported two transactions in Class A common stock. On February 18, 2026, he completed an open-market sale of 13,426 shares at $3.08 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 1,195,349 shares owned directly.
On February 17, 2026, 11,908 shares were disposed of at $3.49 per share to cover tax withholding in connection with the net settlement of restricted stock units. These shares were withheld by the company to satisfy tax obligations rather than sold for discretionary portfolio reasons.
Recursion Pharmaceuticals CEO Najat Khan reported a tax-related share disposition. On February 17, 2026, 14,280 shares of Class A common stock at $3.49 per share were withheld by the company to cover tax obligations tied to restricted stock units. After this withholding, Khan directly owned 2,290,383 shares of Class A common stock. This was a tax-withholding transaction, not an open-market buy or sell.
Christopher C. Gibson reported multiple sales of Class A shares. The filing lists six transactions of 40,000 Class A shares each on 11/19/2025, 12/04/2025, 12/19/2025, 01/05/2026, 01/20/2026, and 02/04/2026, with reported proceeds of 166,400.00, 185,200.00, 180,000.00, 170,000.00, 178,800.00, and 164,800.00, respectively.
RXRX filed a Form 144 reporting an insider sale notice for Class A common stock. The filing lists a proposed sale tied to 02/15/2026 described as Restricted Stock Vesting with the issuer named as the seller. The filing also records a prior sale by Ben Taylor of 21,383 shares on 12/29/2025 for $89,380.94. Broker details include Fidelity Brokerage Services LLC.
Recursion Pharmaceuticals, Inc. reported new equity awards to its CEO and President, Najat Khan. On February 6, 2026, Khan received 1,673,546 shares of Class A common stock for no cash cost through restricted stock units. An additional 30,346 RSU-based shares vested immediately on the grant date.
The large RSU grant vests in equal sixteenth portions, starting May 15, 2026 and then every three months. To cover taxes on these equity awards, 10,364 shares were withheld at a price of $3.98 per share. After these transactions, Khan directly owned 2,304,663 Class A common shares.
Recursion Pharmaceuticals’ Chief Financial Officer Ben R. Taylor reported equity compensation activity. On February 6, 2026, he received 446,279 Class A RSUs that vest in equal sixteenth installments starting May 15, 2026 and every three months afterward, plus 24,254 RSUs that vested immediately.
The company also withheld 11,400 shares at $3.98 per share to satisfy tax obligations from RSU settlement. After these transactions, Taylor directly beneficially owned 1,220,683 shares of Class A Common Stock.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported equity compensation transactions in Class A common stock. On February 6, 2026, he acquired 502,064 shares at $0 per share from a restricted stock unit (RSU) grant that vests in sixteenth installments starting May 15, 2026 and every three months thereafter. He also acquired 24,254 shares at $0 per share from an RSU that vested immediately on the grant date. On the same day, 11,400 shares were withheld at $3.98 per share to cover tax obligations related to RSU settlement. After these transactions, Hallett directly owned 1,109,059 Class A shares.
Recursion Pharmaceuticals director Christopher Gibson reported several stock transactions in early February 2026. On February 4, he converted 40,000 shares of Class B Common Stock into Class A at $0 per share, then sold 40,000 Class A shares at $4.12 under a pre-arranged Rule 10b5-1 trading plan.
On February 6, Gibson received 30,346 Class A shares from restricted stock units that vested immediately at $0, and 10,364 shares were withheld at $3.56 to cover taxes. After these transactions, he directly held 933,821 Class A shares, alongside sizable option and convertible Class B positions.
Recursion Pharmaceuticals director Blake Borgeson sold 220,000 shares of Class A common stock on February 3, 2026 at $4.20 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 31, 2025. After this transaction, he beneficially owned 6,429,863 shares, held directly.
Baillie Gifford & Co reports beneficial ownership of 23,774,972 shares of Recursion Pharmaceuticals, Inc. Class A common stock, representing 4.62% of the class as of December 31, 2025. The firm has sole voting power over 23,730,293 shares and sole dispositive power over all 23,774,972 shares.
The filer identifies itself as an investment adviser and states the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Recursion. The filing confirms ownership has fallen to 5 percent or less of the class.